Literature DB >> 19494715

Perioperative cortisol can predict hypothalamus-pituitary-adrenal status in clinically non-functioning pituitary adenomas.

R Cozzi1, G Lasio, A Cardia, G Felisati, M Montini, R Attanasio.   

Abstract

BACKGROUND: Peri-operative steroids are administered routinely to patients with pituitary adenoma undergoing transsphenoidal adenomectomy (TSA). AIM: To evaluate hypothalamic-pituitary-adrenal (HPA) axis before and after programmed endoscopic TSA (E-TSA) in patients with clinically non-functioning pituitary macroadenoma (NFPA).
DESIGN: Open prospective.
SETTING: Tertiary referral hospitals. PATIENTS: Seventy-two consecutive patients (20-87 yr, 37 males).
INTERVENTIONS: Adrenal steroid replacement therapy (ASRT) was given only in patients with hypocortisolism [08:00 h cortisol (F) <8 microg/dl]. MAIN OUTCOME MEASUREMENTS: After ETSA, achieving wide (>90%) selective resection of the adenoma in all, F and clinical picture were checked at day 2. The low-dose (1 microg) ACTH test (LDACTH) was performed at 6 weeks and repeated at 12 months.
RESULTS: Hypocortisolism was present pre-operatively in 14 patients (19.4%), persisted post-operatively in all but one, and was detected de novo at the post-operative day 2 control in 6 (10.3%). In all but one the post-operative day 2 basal F and peak F during LDACTH test were concordant. No patient whose F was > 8 microg/dl was treated with ASRT or developed symptoms of adrenal failure during the follow-up (1-11 yr, median 5).
CONCLUSIONS: HPA function is usually preserved in NFPA and is infrequently impaired after complete tumor removal by E-TSA. The 08:00 h. plasma cortisol evaluation before and 2 days after surgery, using as cut-off the value of 8 microg/dl, allows full evaluation of HPA status. Peri-operative steroid treatment should be given only in patients with hypocortisolism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19494715     DOI: 10.1007/BF03346486

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  43 in total

1.  Establishment of reference values for standard dose short synacthen test (250 microgram), low dose short synacthen test (1 microgram) and insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in normal subjects.

Authors:  J Gonzálbez; C Villabona; J Ramón; M A Navarro; O Giménez; W Ricart; J Soler
Journal:  Clin Endocrinol (Oxf)       Date:  2000-08       Impact factor: 3.478

2.  The learning curve in endoscopic pituitary surgery and our experience.

Authors:  Kenan Koc; Koc Kenan; Ihsan Anik; Anik Ihsan; Dilek Ozdamar; Ozdamar Dilek; Burak Cabuk; Cabuk Burak; Gurkan Keskin; Keskin Gurkan; Savas Ceylan; Ceylan Savas
Journal:  Neurosurg Rev       Date:  2006-08-26       Impact factor: 3.042

3.  Evaluation of the pituitary-adrenal axis before, during and after pituitary adenomectomy. Is perioperative glucocorticoid therapy necessary?

Authors:  P P García-Luna; A Leal-Cerro; J L Rocha; F Trujillo; F Garcia-Pesquera; R Astorga
Journal:  Acta Endocrinol (Copenh)       Date:  1990-01

Review 4.  Dose-response aspects in the clinical assessment of the hypothalamo-pituitary-adrenal axis, and the low-dose adrenocorticotropin test.

Authors:  W Oelkers
Journal:  Eur J Endocrinol       Date:  1996-07       Impact factor: 6.664

5.  Adrenocortical insufficiency after pituitary surgery: an audit of the reliability of the conventional short synacthen test.

Authors:  M Klose; M Lange; M Kosteljanetz; L Poulsgaard; U Feldt-Rasmussen
Journal:  Clin Endocrinol (Oxf)       Date:  2005-11       Impact factor: 3.478

6.  Reproducibility of the insulin tolerance test (ITT) for assessment of growth hormone and cortisol secretion in normal and hypopituitary adult men.

Authors:  M Pfeifer; K Kanc; R Verhovec; A Kocijancic
Journal:  Clin Endocrinol (Oxf)       Date:  2001-01       Impact factor: 3.478

Review 7.  Diagnosis of adrenal insufficiency.

Authors:  Richard I Dorin; Clifford R Qualls; Lawrence M Crapo
Journal:  Ann Intern Med       Date:  2003-08-05       Impact factor: 25.391

8.  Endoscopic transsphenoidal treatment in recurrent and residual pituitary adenomas--first experience.

Authors:  A Rudnik; T Zawadzki; B Gałuszka-Ignasiak; P Bazowski; I Duda; M Wojtacha; A I Rudnik; I Krawczyk
Journal:  Minim Invasive Neurosurg       Date:  2006-02

9.  Hydrocortisone dose and postoperative diabetes insipidus in patients undergoing transsphenoidal pituitary surgery: a prospective randomized controlled study.

Authors:  S Rajaratnam; M S Seshadri; M J Chandy; V Rajshekhar
Journal:  Br J Neurosurg       Date:  2003-10       Impact factor: 1.596

10.  The one microgram adrenocorticotropin test in the assessment of hypothalamic-pituitary-adrenal function.

Authors:  B Ambrosi; L Barbetta; T Re; E Passini; G Faglia
Journal:  Eur J Endocrinol       Date:  1998-12       Impact factor: 6.664

View more
  9 in total

Review 1.  Guidelines in the management of CNS tumors.

Authors:  Navid Redjal; Andrew S Venteicher; Danielle Dang; Andrew Sloan; Remi A Kessler; Rebecca R Baron; Constantinos G Hadjipanayis; Clark C Chen; Mateo Ziu; Jeffrey J Olson; Brian V Nahed
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

Review 2.  The role of radiation therapy in the management of non-functioning pituitary adenomas.

Authors:  M Losa; P Picozzi; M Motta; M Valle; A Franzin; P Mortini
Journal:  J Endocrinol Invest       Date:  2011-03-22       Impact factor: 4.256

3.  Perioperative Outcomes of a Hydrocortisone Protocol after Endonasal Surgery for Pituitary Adenoma Resection.

Authors:  Tyler D Alexander; Sarah Collopy; Siyuan Yu; Michael Karsy; Chandala Chitguppi; Christopher J Farrell; James J Evans
Journal:  J Neurol Surg B Skull Base       Date:  2021-09-27

Review 4.  Investigation of the Hypothalamo-pituitary-adrenal (HPA) axis: a contemporary synthesis.

Authors:  Zuleyha Karaca; Ashley Grossman; Fahrettin Kelestimur
Journal:  Rev Endocr Metab Disord       Date:  2021-03-26       Impact factor: 6.514

Review 5.  Is peri-operative steroid replacement therapy necessary for the pituitary adenomas treated with surgery? A systematic review and meta analysis.

Authors:  Mamatemin Tohti; Junyang Li; Yuan Zhou; Yuebing Hu; Zhuang Yu; Chiyuan Ma
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

6.  Recovery Room Cortisol Predicts Long-Term Glucocorticoid Need After Transsphenoidal Surgery for Pituitary Tumors.

Authors:  Amro Qaddoura; Tenzin N Shalung; Michael P Meier; Jeannette Goguen; Rowan Jing; Stanley Zhang; Kalman Kovacs; Michael D Cusimano
Journal:  Neurosurgery       Date:  2019-03-01       Impact factor: 4.654

7.  Endoscopic endonasal trans-sphenoid surgery of pituitary adenoma.

Authors:  Yr Yadav; S Sachdev; V Parihar; H Namdev; Pr Bhatele
Journal:  J Neurosci Rural Pract       Date:  2012-09

8.  Perioperative serum cortisol levels in ACTH sufficient and ACTH deficient patients during transsphenoidal surgery of pituitary adenoma.

Authors:  Henrik Borg; Peter Siesjö; Babar Kahlon; Sigridur Fjalldal; Eva Marie Erfurth
Journal:  Endocrine       Date:  2018-07-02       Impact factor: 3.633

9.  Postoperative day 1 versus postoperative day 5 morning cortisol for predicting an intact hypothalamic-pituitary axis: A cohort analysis.

Authors:  Esther Dupepe; Daxa Patel; Joseph Miller; Ivania Rizo; Tom Brooks Vaughan; Kristen Riley
Journal:  Surg Neurol Int       Date:  2019-06-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.